MeSH D009503 - neutropenia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Abbott Biotherapeutics | Amphotericin b | Amphotericin B |  | 1996-12-23 |  |  |
| Accord Healthcare | Filgrastim | Accofil |  | 2014-09-17 |  |  |
| Filgrastim | Grastofil |  | 2013-10-17 |  |  | |
| Itraconazole | Itraconazole |  | 2016-05-26 |  |  | |
| Pegfilgrastim | Pelgraz |  | 2018-09-21 |  |  | |
| Alembic Pharmaceuticals | Itraconazole | Itraconazole |  | 2016-12-13 |  |  |
| ALK-Abelló | Ciprofloxacin | Otiprio | 2029-04-21 | 2015-12-10 |  |  |
| Alkem Laboratories | Itraconazole | Itraconazole |  | 2017-06-12 |  |  |
| Vancomycin | Vancomycin |  | 2022-11-14 |  |  | |
| Alkopharma USA | Amphotericin b | Amphotec |  | 1996-11-22 |  |  |
| Allergan | Ciprofloxacin | Ciprofloxacin |  | 2005-01-21 |  |  |
| Vancomycin | Vancomycin |  | 2012-04-09 |  |  | |
| Altaire Pharmaceuticals | Ciprofloxacin | Ciprofloxacin |  | 2018-05-03 |  |  |
| Amgen | Pegfilgrastim | Neulasta |  | 2002-08-22 | $1,126 M | Y2022 |
| Pegfilgrastim | Neulasta Onpro |  | 2002-01-31 |  |  | |
| Filgrastim | Neupogen |  | 1991-02-20 | $155 M | Y2013 | |
| Pegfilgrastim | Ristempa |  | 2015-04-13 |  |  | |
| Amneal Pharmaceuticals | Ciprofloxacin | Ciprofloxacin |  | 2004-06-09 |  |  |
| Itraconazole | Itraconazole |  | 2016-09-26 |  |  | |
| Vancomycin | Vancomycin |  | 2023-06-23 |  |  |
1
2
3
4
5
6
...
9
>
Clinical Trials
Historical Success Rate
Phase 1
67%26/39
Phase 2
48%27/56
Phase 3
48%26/54
Approved: 15Overall Success rate: 15%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use